...
首页> 外文期刊>Biochimica et biophysica acta. Biomembranes >Restoring pulmonary surfactant membranes and films at the respiratory surface
【24h】

Restoring pulmonary surfactant membranes and films at the respiratory surface

机译:在呼吸表面恢复肺表面活性剂膜和薄膜

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Abstract Pulmonary surfactant is a complex of lipids and proteins assembled and secreted by the alveolar epithelium into the thin layer of fluid coating the respiratory surface of lungs. There, surfactant forms interfacial films at the air-water interface, reducing dramatically surface tension and thus stabilizing the air-exposed interface to prevent alveolar collapse along respiratory mechanics. The absence or deficiency of surfactant produces severe lung pathologies. This review describes some of the most important surfactant-related pathologies, which are a cause of high morbidity and mortality in neonates and adults. The review also updates current therapeutic approaches pursuing restoration of surfactant operative films in diseased lungs, mainly through supplementation with exogenous clinical surfactant preparations. This article is part of a Special Issue entitled: Membrane Lipid Therapy: Drugs Targeting Biomembranes edited by Pablo V. Escribá. Graphical abstract Display Omitted Highlights ? Exogenous surfactant supplementation has saved thousands of lives of preterm neonates. ? Development of humanized clinical surfactants is a main motivation for current research. ? Meconium aspiration syndrome associates with inactivation of surfactant at different levels. ? Surfactant therapy in MAS or ARDS depends on production of enhanced inhibition-resistant surfactants. ]]>
机译:摘要肺表面活性剂是脂质和蛋白质的复合物组装并由肺泡上皮分泌到涂覆肺呼吸表面的薄层中。在那里,表面活性剂在空气 - 水界面处形成界面薄膜,从而降低急剧表面张力,从而稳定空气暴露的界面,以防止沿着呼吸力学的肺泡塌陷。表面活性剂的缺失或缺乏产生严重的肺病理。该评论描述了一些与最重要的表面活性剂相关病理学,这是新生儿和成人中发病率和死亡率高的原因。审查还更新了当前治疗方法,追求患病肺部的表面活性剂手术薄膜,主要通过补充与外源临床表面活性剂制剂进行补充。本文是标题的特殊问题的一部分:膜脂质疗法:靶向PabloV.Scribá编辑的生物膜的药物。图形抽象显示省略了亮点?外源性表面活性剂补充拯救了成千上万的早产新生儿。还人性化临床表面活性剂的发展是目前研究的主要动机。还Mechonium抽吸综合征在不同层次的表面活性剂中缔合的缔合物。还MAS或ARD中的表面活性剂治疗取决于产生增强的抑制表面活性剂。 ]]>

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号